Chinese companies independently researched and developed new crown + A and B stream joint detection kits approved for listing

Medical Network, August 23.
Nucleic acid testing is a "gold standard" for diagnosing new coronary pneumonia and an important means of preventing and controlling the epidemic
.
Fever, sore throat, myalgia, dry cough, fatigue, etc.
are common symptoms of patients with new coronary pneumonia and influenza.
In influenza, imaging lung patches and ground glass shadows may also appear
.

 

How to quickly identify under the prevention and control of the new crown epidemic? While avoiding misdiagnosis and missed diagnosis, reducing the pressure on medical staff and improving medical efficiency has become a topic of thought in the industry
.

 

The new crown combined influenza A and B virus nucleic acid detection kit independently developed and produced by Chinese biomedical science and technology enterprises has been approved by the National Medical Products Administration.
While filling the gap in related fields, it has added to the pathogen identification of patients with suspected influenza and new crown symptoms.
Convenient and effective new tools
.
This innovative product is the first domestically approved COVID-19 joint inspection product based on a fluorescent quantitative PCR platform, and has attracted a lot of attention once it came out
.

 

　　Dr.
Xiong Lei, the founder and chairman of Shanghai Silidi Biomedical Technology Co.
, Ltd.
, pointed out in an interview with a reporter from Chinanews.
com on the 22nd that the prevention and control of the new crown epidemic is normalized, and nucleic acid detection capabilities are the first "gate" to prevention and control
.
He believes that China's current nucleic acid testing capabilities are already strong and popularized.
As the situation of China's epidemic prevention and control is getting better and better, the people are gradually returning to normal life
.
Autumn and winter are the seasons for the high incidence of influenza, and the incidence of influenza may gradually pick up in the future.
Symptoms similar to those of new coronary pneumonia will cause distress to doctors and patients and increase anxiety
.

 

　　It is known that upper respiratory tract infection common pathogens, including viruses, mycoplasma, bacteria three categories, including infection caused by a viral infection of the respiratory tract diseases accounted for more than 85% of the total
.
Strong contagion has allowed influenza to circulate in humans for more than 100 years, and symptoms similar to those of the new coronavirus infection have increased the pressure on prevention and control
.

 

　　During the interview, the reporter learned that the COVID-19 combined with influenza A and B virus nucleic acid detection kit independently developed by Chinese companies and approved to be marketed was designed to overcome the mutual influence and interference between influenza virus and COVID-19.
High sensitivity and high precision can be avoided.
Misjudgment and missed inspection occurred during inspection
.

 

　　Xiong Lei said that in autumn and winter, temperature changes will intensify.
If the incidence of the new crown epidemic superimposed on influenza increases, it is necessary to accurately rule out the possibility of influenza or new crown virus for newly diagnosed patients with respiratory infection symptoms.
According to routine screening, at least two tests are required
.
How to save time and economic costs? In fact, the medical community has paid attention to this topic
.
Earlier, the United States had approved the similar "simplified version" of the influenza-combined COVID-19 nucleic acid test kit in an emergency
.

 

　　It is understood that the new crown combined influenza A and B virus nucleic acid detection kit independently developed and approved by the Chinese company this time has all technical indicators and sensitivity higher than previous foreign products
.
The registration inspection report issued by the China Institute for Food and Drug Control shows that the combined detection kits for the detection of the new coronavirus and different subtypes of influenza viruses are superior to the national registration and inspection requirements
.

 

　　In Xiong Lei's view, the new crown combined with influenza A and B virus nucleic acid detection kits have been approved for marketing.
After being promoted in fever clinics, respiratory outpatient clinics and pediatric outpatient clinics, it will make the current new crown, influenza screening, diagnosis and treatment processes and systems more complete
.
This combined detection kit can optimize the diagnosis process, improve efficiency, avoid panic, and make medical expenditures more economical and reasonable
.

 

　　According to Dr.
Chen Caifu, Chief Technology Officer (CTO) of Siddi Diagnostics, this new crown combined influenza A and B virus nucleic acid detection kit was included in the Emergency Use Listing (EUL) of the World Health Organization (WHO) last year
.
It is understood that EUL is similar to China's fast track for product emergency approval
.

 

　　It is understood that after graduating from the Institute of Biochemistry of the Chinese Academy of Sciences, Xiong Lei went to the University of Zurich in Switzerland for further studies
.
In 2010, Xiong Lei returned to China after his studies, and founded Sidi Di in Shanghai
.
Turning to bio- pharmaceutical development, Xiong Lei believes that Shanghai has a good environment for the development of bio-medicine; at the same time, research institutes and R & D infrastructure strength, efficient administrative capacity, quality of the business environment as well as government departments and pragmatic atmosphere, combined with The leading position of the Yangtze River Delta region attracts overseas talents
.
He told reporters that his company has gathered dozens of high-level talents from Europe, Australia, North America, Singapore and other countries and regions .
They all like to work and study in Shanghai
.
He is very optimistic about the development of Shanghai and even China's biomedical industry, and is full of confidence in the future of the industry and enterprises
.

 

　　Regarding the advent of the new detection kit, the reporter learned that at the beginning of the outbreak of the new crown pneumonia epidemic, on January 24, 2020, on New Year’s Eve, Dr.
Lei Xiong initiated a call for research and development.
Dr.
Caifu Chen, Chief Technology Officer (CTO) of Diagnosis Under the leadership of the company, a product development team of more than forty people has invested in research and development during the Spring Festival
.
Xiong Lei told reporters that the Shanghai Food and Drug Administration gave a priority review recommendation after learning about the performance of related products in detail, which greatly shortened the time for review and approval
.
In addition, the new detection kit has successively received technical innovation funds from the "Science and Technology Innovation Action Plan" of the Shanghai Municipal Science and Technology Commission and special development funds for the establishment of Zhangjiang National Independent Innovation Demonstration Zone by the Municipal Science and Technology Commission
.

 

　　On the same day, the Shanghai Municipal Commission of Economy and Information Technology also told reporters that for products that are of great significance to the prevention and control of the epidemic, the commission will work hard to coordinate relevant departments to give policies and other tilts to help rapid promotion
.
(over)

　　Medical Network, August 23.
Nucleic acid testing is a "gold standard" for diagnosing new coronary pneumonia and an important means of preventing and controlling the epidemic
.
Fever, sore throat, myalgia, dry cough, fatigue, etc.
are common symptoms of patients with new coronary pneumonia and influenza.
In influenza, imaging lung patches and ground glass shadows may also appear
.

 

　　How to quickly identify under the prevention and control of the new crown epidemic? While avoiding misdiagnosis and missed diagnosis, reducing the pressure on medical staff and improving medical efficiency has become a topic of thought in the industry
.

 

　　The new crown combined influenza A and B virus nucleic acid detection kit independently developed and produced by Chinese biomedical science and technology enterprises has been approved by the National Medical Products Administration.
While filling the gap in related fields, it has added to the pathogen identification of patients with suspected influenza and new crown symptoms.
Convenient and effective new tools
.
This innovative product is the first domestically approved COVID-19 joint inspection product based on a fluorescent quantitative PCR platform, and has attracted a lot of attention once it came out
.

 

　　Dr.
Xiong Lei, the founder and chairman of Shanghai Silidi Biomedical Technology Co.
, Ltd.
, pointed out in an interview with a reporter from Chinanews.
com on the 22nd that the prevention and control of the new crown epidemic is normalized, and nucleic acid detection capabilities are the first "gate" to prevention and control
.
He believes that China's current nucleic acid testing capabilities are already strong and popularized.
As the situation of China's epidemic prevention and control is getting better and better, the people are gradually returning to normal life
.
Autumn and winter are the seasons for the high incidence of influenza, and the incidence of influenza may gradually pick up in the future.
Symptoms similar to those of new coronary pneumonia will cause distress to doctors and patients and increase anxiety
.

 

　　It is known that upper respiratory tract infection common pathogens, including viruses, mycoplasma, bacteria three categories, including infection caused by a viral infection of the respiratory tract diseases accounted for more than 85% of the total
.
Strong contagion has allowed influenza to circulate in humans for more than 100 years, and symptoms similar to those of the new coronavirus infection have increased the pressure on prevention and control
.

 

　　During the interview, the reporter learned that the COVID-19 combined with influenza A and B virus nucleic acid detection kit independently developed by Chinese companies and approved to be marketed was designed to overcome the mutual influence and interference between influenza virus and COVID-19.
High sensitivity and high precision can be avoided.
Misjudgment and missed inspection occurred during inspection
.

 

　　Xiong Lei said that in autumn and winter, temperature changes will intensify.
If the incidence of the new crown epidemic superimposed on influenza increases, it is necessary to accurately rule out the possibility of influenza or new crown virus for newly diagnosed patients with respiratory infection symptoms.
According to routine screening, at least two tests are required
.
How to save time and economic costs? In fact, the medical community has paid attention to this topic
.
Earlier, the United States had approved the similar "simplified version" of the influenza-combined COVID-19 nucleic acid test kit in an emergency
.

 

　　It is understood that the new crown combined influenza A and B virus nucleic acid detection kit independently developed and approved by the Chinese company this time has all technical indicators and sensitivity higher than previous foreign products
.
The registration inspection report issued by the China Institute for Food and Drug Control shows that the combined detection kits for the detection of the new coronavirus and different subtypes of influenza viruses are superior to the national registration and inspection requirements
.

 

　　In Xiong Lei's view, the new crown combined with influenza A and B virus nucleic acid detection kits have been approved for marketing.
After being promoted in fever clinics, respiratory outpatient clinics and pediatric outpatient clinics, it will make the current new crown, influenza screening, diagnosis and treatment processes and systems more complete
.
This combined detection kit can optimize the diagnosis process, improve efficiency, avoid panic, and make medical expenditures more economical and reasonable
.

 

　　According to Dr.
Chen Caifu, Chief Technology Officer (CTO) of Siddi Diagnostics, this new crown combined influenza A and B virus nucleic acid detection kit was included in the Emergency Use Listing (EUL) of the World Health Organization (WHO) last year
.
It is understood that EUL is similar to China's fast track for product emergency approval
.

 

　　It is understood that after graduating from the Institute of Biochemistry of the Chinese Academy of Sciences, Xiong Lei went to the University of Zurich in Switzerland for further studies
.
In 2010, Xiong Lei returned to China after his studies, and founded Sidi Di in Shanghai
.
Turning to bio- pharmaceutical development, Xiong Lei believes that Shanghai has a good environment for the development of bio-medicine; at the same time, research institutes and R & D infrastructure strength, efficient administrative capacity, quality of the business environment as well as government departments and pragmatic atmosphere, combined with The leading position of the Yangtze River Delta region attracts overseas talents
.
He told reporters that his company has gathered dozens of high-level talents from Europe, Australia, North America, Singapore and other countries and regions .
They all like to work and study in Shanghai
.
He is very optimistic about the development of Shanghai and even China's biomedical industry, and is full of confidence in the future of the industry and enterprises
.

 

　　Regarding the advent of the new detection kit, the reporter learned that at the beginning of the outbreak of the new crown pneumonia epidemic, on January 24, 2020, on New Year’s Eve, Dr.
Lei Xiong initiated a call for research and development.
Dr.
Caifu Chen, Chief Technology Officer (CTO) of Diagnosis Under the leadership of the company, a product development team of more than forty people has invested in research and development during the Spring Festival
.
Xiong Lei told reporters that the Shanghai Food and Drug Administration gave a priority review recommendation after learning about the performance of related products in detail, which greatly shortened the time for review and approval
.
In addition, the new detection kit has successively received technical innovation funds from the "Science and Technology Innovation Action Plan" of the Shanghai Municipal Science and Technology Commission and special development funds for the establishment of Zhangjiang National Independent Innovation Demonstration Zone by the Municipal Science and Technology Commission
.

 

　　On the same day, the Shanghai Municipal Commission of Economy and Information Technology also told reporters that for products that are of great significance to the prevention and control of the epidemic, the commission will work hard to coordinate relevant departments to give policies and other tilts to help rapid promotion
.
(over)